Graybug to merge with CalciMedica; combined company focused on Auxora for inflammatory diseases

CalciMedica, Inc.

Graybug holders to own ~29% of combined co; CalciMedica holders ~71% (based on $40M and $100M valuations).
Combined co expected to have ~$35M cash at close, with runway into H2 2024; includes ~$10.3M private placement.
Auxora Phase 2b AP data expected H2 2023; Phase 1/2 AAP data H1 2023; potential accelerated approval path.
Rachel Leheny (CalciMedica CEO) to lead combined co; board 5 CalciMedica / 2 Graybug; close expected Q1 2023.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CalciMedica, Inc. entered into Agreement and Plan of Merger and Reorganization with CalciMedica, Inc. (effective 2022-11-21).

Action: entry
Agreement: merger
Counterparty: CalciMedica, Inc.
Effective: 2022-11-21

Exact text from the filing

On November 21, 2022, Graybug Vision, Inc., a Delaware corporation (“ Graybug ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”) with CalciMedica, Inc., a Delaware corporation (“ CalciMedica ”), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for serious inflammatory diseases with high unmet need, and Camaro Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Graybug (“ Merger Sub ”).

View on SEC.gov

622 material agreements filed in the last 30 days. Browse all material agreements →

CalciMedica, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-290244

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.